Unjha Formulations Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 782664,
    "name": "Unjha Formul.",
    "stock_name": "Unjha Formul.",
    "full_name": "Unjha Formulations Ltd",
    "name_url": "stocks-analysis/unjha-formul",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "18.97",
    "chg": 1.42,
    "chgp": "8.09%",
    "dir": 1,
    "prev_price": "17.55",
    "mcapval": "8.50 Cr",
    "mcap": "Micro Cap",
    "scripcode": 531762,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE576D01015",
    "curr_date": "Jun 18",
    "curr_time": "",
    "bse_nse_vol": "2.2 k",
    "exc_status": "Active",
    "traded_date": "Jun 18, 2026",
    "traded_date_str": "2026 06 18",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://marketsmojo.motilaloswal.com/MOSL-Landingstocks-analysis/unjha-formul-782664-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Are Unjha Formulations Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-unjha-formulations-ltd-latest-results-good-or-bad-3999521",
        "imagepath": "",
        "date": "2026-05-19 19:17:21",
        "description": "Unjha Formulations Ltd's Q4 FY26 results highlight a complex operational landscape characterized by significant revenue growth juxtaposed with widening losses. The company reported net sales of ₹3.28 crores for the quarter, reflecting a year-on-year increase of 38.40% from ₹2.37 crores in Q4 FY25. However, this revenue growth did not translate into profitability, as the company experienced a net loss of ₹0.74 crores, which is a deterioration from the loss of ₹0.41 crores in the same quarter last year.\n\nThe quarter-on-quarter performance reveals further challenges, with a notable decline in revenue of 25.62% from ₹4.41 crores in Q3 FY26. This decline coincided with a shift from a profit of ₹0.24 crores in the previous quarter to a loss of ₹0.74 crores, raising concerns about the company's operational stability.\n\nOperating margins also reflected significant strain, with an operating margin of -13.72% in Q4 FY..."
      },
      {
        "title": "Unjha Formulations Ltd Upgraded to Sell on Technical Improvement Despite Mixed Fundamentals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/unjha-formulations-ltd-upgraded-to-sell-on-technical-improvement-despite-mixed-fundamentals-3969563",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/UnjhaFormulatio_mojoScore_3969563.png",
        "date": "2026-04-30 08:03:55",
        "description": "Unjha Formulations Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 29 April 2026, driven primarily by a shift in technical indicators despite persistent fundamental challenges. The micro-cap pharmaceutical company’s Mojo Score has improved to 31.0, reflecting a nuanced change in market sentiment and technical trends, even as financial performance remains flat and long-term fundamentals show weaknesses."
      },
      {
        "title": "Markets Rally, But Unjha Formulations Ltd Sinks to 52-Week Low in Stock-Specific Sell-Off",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/unjha-formulations-ltd-falls-to-52-week-low-of-rs186-amid-market-pressure-3935953",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/UnjhaFormulatio_priceRelatedfactors_3935953.png",
        "date": "2026-04-07 12:05:09",
        "description": ""
      },
      {
        "title": "Markets Rally, But Unjha Formulations Ltd Sinks to 52-Week Low in Stock-Specific Sell-Off",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/unjha-formulations-ltd-falls-to-52-week-low-of-rs1899-amid-market-downturn-3930348",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/UnjhaFormulatio_priceRelatedfactors_3930348.png",
        "date": "2026-04-02 10:43:07",
        "description": ""
      }
    ],
    "total": 9,
    "sid": "782664",
    "stock_news_url": "https://marketsmojo.motilaloswal.com/news/unjha-formulations-782664"
  },
  "announcements": [
    {
      "caption": "Outcome Of Board Meeting - Appointment Of Company Secretary And Compliance Officer.",
      "datetime": "01-Jun-2026",
      "details": "REGULATION 6(1) AND 30(4) WITH PART A OF SCH II OF SEBI(LODR)REGULATION2015",
      "source": "BSE"
    },
    {
      "caption": "Publish Audited Financial Results For The Quarter And Year Ended As On 31/03/2026",
      "datetime": "20-May-2026",
      "details": "Regulation 33(3) of SEBI (lodr) 2015",
      "source": "BSE"
    },
    {
      "caption": "Publish Audited Financial Results For The Quarter And Year Ended As On 31/03/2026",
      "datetime": "20-May-2026",
      "details": "Regulation 33(3) of SEBI (lodr) 2015",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Are Unjha Formulations Ltd latest results good or bad?

2026-05-19 19:17:21

Unjha Formulations Ltd's Q4 FY26 results highlight a complex operational landscape characterized by significant revenue growth juxtaposed with widening losses. The company reported net sales of ₹3.28 crores for the quarter, reflecting a year-on-year increase of 38.40% from ₹2.37 crores in Q4 FY25. However, this revenue growth did not translate into profitability, as the company experienced a net loss of ₹0.74 crores, which is a deterioration from the loss of ₹0.41 crores in the same quarter last year. The quarter-on-quarter performance reveals further challenges, with a notable decline in revenue of 25.62% from ₹4.41 crores in Q3 FY26. This decline coincided with a shift from a profit of ₹0.24 crores in the previous quarter to a loss of ₹0.74 crores, raising concerns about the company's operational stability. Operating margins also reflected significant strain, with an operating margin of -13.72% in Q4 FY...

Unjha Formulations Ltd Upgraded to Sell on Technical Improvement Despite Mixed Fundamentals

2026-04-30 08:03:55

Unjha Formulations Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 29 April 2026, driven primarily by a shift in technical indicators despite persistent fundamental challenges. The micro-cap pharmaceutical company’s Mojo Score has improved to 31.0, reflecting a nuanced change in market sentiment and technical trends, even as financial performance remains flat and long-term fundamentals show weaknesses.

Markets Rally, But Unjha Formulations Ltd Sinks to 52-Week Low in Stock-Specific Sell-Off

2026-04-07 12:05:09

Markets Rally, But Unjha Formulations Ltd Sinks to 52-Week Low in Stock-Specific Sell-Off

2026-04-02 10:43:07

View All News